Introduction of Prof. Van de Werf
As principal investigator, could you please summarise the rationale for the STREAM trial?
Could you describe the trial design of STREAM?
There have been other pharmaco-invasive trials (TRANSFER-AMI, CARESS-in AMI, NORDISTEMI). In which aspect does the STREAM trial differ to these trials?
What were the main outcomes of STREAM?
Do you think the results of the STREAM trial will change the clinical practice of STEMI patients? Will there be differences in practice across the world?
Do you think the results of STREAM will have any impact on the guidelines for STEMI and if so, what is this likely to be?